All News
occurrence of extra-articulations manifestations is high & increases over time
#ACR19 @rheumnow 4M064 https://t.co/QC62S7cvPk
Dr Irwin Lim _connectedcare ( View Tweet)
If appendix removed by age 25 for true appendicitis, won’t get UC (can still get crohns)...fascinating 🤔 -Dr D Rubin #ACR19 @RheumNow
Maeve Gamble MaeveGamble ( View Tweet)
Holy Molly! TNFi (etanercept, adalimumab, infliximab, or golimumab) completely prevented stokes in patients with DADA2. #ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
#ACR19 @rheumnow ABS1513 Tofacitinib efficacy in PSA ⬇️ if BL BMI ≥ 35 . Safety consistent across all BL BMI categories. 3 CV events: non-fatal cerebrovascular accident, TIA(both Tofa 5 mg BID, BMI ≥ 30 – < 35), and artery revascularization in PBO; BMI ≥ 35 https://t.co/Y8htX6qETV
Olga Petryna DrPetryna ( View Tweet)
#ACR19 @rheumnow abs1913 Cohort study confirms the association of HLA-B*15 with peripheral joint involvement in AS but not in PSA, suggesting different mechanisms may be in play in the pathogenesis of peripheral joint and entheseal involvement between AS &PSA https://t.co/NdaHqI63oH
Olga Petryna DrPetryna ( View Tweet)
@AmandaOmbrello from @NIH_NIAMS at #ACR19 :
#Rheumatologists... Have you come across Adult-Onset Sporadic #PolyarteritisNodosa ?...
🚨 Don’t forget to check for ADA2 mutation!!! 🚨
@ACRheum @RheumNow https://t.co/1MP0wsD6Vr
Adam Kilian MD KilianMD ( View Tweet)
60%
The percentage of patients at @NIH's autoinflammatory disease cohort that are undifferentiated and do not have a specific disease diagnosis -Dr. Amanda Ombrello. #ACR19 @rheumnow https://t.co/d85OtnEA8o
Jonathan Hausmann MD hausmannMD ( View Tweet)
H2H Vedo vs Ada for gut disease (not joint)(no dose escalation in this trial)
#ACR19 @rheumnow 4M064 https://t.co/30JhLETdAK
Dr Irwin Lim _connectedcare ( View Tweet)
Panel on podcasting in rheumatology led by @RheumNow with @AdamJBrownMD @hausmannMD @EBRheum and myself. #ACR19 https://t.co/W1EMXe2qsd
Dr. Paul Sufka psufka ( View Tweet)
Shared & separate targets for autoimmune bowel disease & SpA. Nice summary
#ACR19 @rheumnow 4M064 https://t.co/5Mz7pM0hPv
Dr Irwin Lim _connectedcare ( View Tweet)
Treatment of patients with haploinsufficiency 20 (HA20) responds to HIGH (500mg!) doses of anakinra, TNF inhibitors, or--recently--JAK inhibitors. @AmandaOmbrello #ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
The questions that Dr. Amanda Ombrello (@NIH) asks when evaluating patients with recurrent fevers: -Age of onset -Frequency -Duration -Regularity -Height of fever -Prodromal symptoms #ACR19 @rheumnow
Jonathan Hausmann MD hausmannMD ( View Tweet)
Can lowering #uricacid improve hepatic fibrosis? Dr Naomi Schlesinger presented data from pegloticase #gout studies showing improvement/prevention of worsening vs pbo via the Fib-4 score Changes esp marked in pts with clinically important baseline Fib-4 score @RheumNow #ACR2019 https://t.co/8QUZvlcf57
Gout Study Group GoutGroup ( View Tweet)
PATCH: HCQ reduces congenital heart block (CHB) recurrence in babies born to Ro+ mothers w/ sibilings w/ CHB. This is encouraging data that further supports treatment induction in Ro+ pregnant pts to decrease fetal risk. https://t.co/0uU1zZP80l Plenary abs#1761 #ACR19 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
“It’s so rare that a lupus clinical trial makes it to a plenary session...so cherish the moment!” -Dr Richard Furie on anifrolumab in SLE 🤣 #ACR19 @RheumNow
Maeve Gamble MaeveGamble ( View Tweet)
TULIP1 Anifrolumab RCT in SLE
Did NOT meet primary endpt SIR4 wk52 (36% v 40% PLBO, NS)
Post Hoc BICLA response DID favor Tx (46% v 30%, NNT~6)
Richard Furie: "Medication rules and endpoint selection are critical for SLE trials." Agreed.
#ACR19 Abst#1763 #ACRBest @RheumNow https://t.co/R4ily1Ubrz
Mike Putman EBRheum ( View Tweet)
Neonatal complete heart block is one to avoid. In Ro-pos mothers with a prev child with CHB, HCQ reduces rates from a historic 20% to 7.4% in the PATCH study. It seems we’re yet to fully realize the power of HCQ in conditions like these!
@nyuschoolofmed #ACR19 ABST1761 @RheumNow https://t.co/TMzmq6TjJx
David Liew drdavidliew ( View Tweet)
#ACR19 @Rheumnow ABS1217 pegadricase (0.2 mg/kg) +ImmTOR (0.15 mg/kg) selected for HtoH study of SEL-212 vs pegloticase based on Ph2T result showing addition of ImmTOR at ≥0.1 mg/kg ⬇️ ADA formation & 66% of pts maintained sUA levels < 6 mg/dL at Wk20.
Olga Petryna DrPetryna ( View Tweet)
Loving the aesthetics of the #ACR19 conference center this year. @RheumNow https://t.co/MOZgNDlfzw
Dr. Paul Sufka psufka ( View Tweet)
HOPE results: 6 week tapering treatment with po prednisolone in HOA pts improved VAS scores and US synovitis. Will this change the way you approach HOA? https://t.co/0MtW7esExU Plenary abs#1760 #ACR19 @RheumNow https://t.co/U5SStHuJoh
Dr. Rachel Tate uptoTate ( View Tweet)